Idera and Merck Extend R&D Deal

Xconomy Boston — 

Idera Pharmaceuticals (NASDAQ:IDRA), a Cambridge, MA-based developer of drugs that target a family of immune system receptors, reports it has inked a one-year extension to its research collaboration with New Jersey-based drug giant Merck. The two companies began the collaboration in December 2006 to investigate Idera’s drugs as treatments for cancer, infectious diseases, and Alzheimer’s.